

# Top Investors - Biotech, Part 2

Completed May 8, 2020



Fidelman & Co.



PART 1

<b>Top Investors - Biotech: Alexandria Venture, Perceptive Advisors</b>	5
<b>Alexandria Venture Investments</b>	5
Investments	5
Points of Contact	6
Data from Initial Research	6
<b>Perceptive Advisors</b>	6
Investments	6
Points of Contact	6
Data From Initial Research	6

PART 2

<b>Top Investors - Biotech: ARCH Venture Partners, Google Ventures</b>	8
<b>Arch Venture Partners</b>	8
Overview	8
Investments	8
Points of Contact	9
Initial Research	9
<b>Google Ventures (GV)</b>	9
Overview	9
Investments	9
Points of Contact	9
Initial Research	10

## PART 3

<b>Top Investors - Biotech: Boxer Capital, OrbiMed</b>	11
<b>Boxer Capital</b>	11
<b>Investments</b>	11
<b>Additional Points of Contact</b>	11
<b>OrbiMed</b>	12
<b>Investments</b>	12
<b>Additional Points of Contact</b>	12

## PART 4

<b>Top Investors - Biotech: Redmile Group, Osage University Partners</b>	13
<b>Redmile Group</b>	13
<b>Biotech Investments</b>	13
<b>Points of Contact at Biotech</b>	13
<b>Strategy Data: Biotech's investments in 2019 and 2020:</b>	14
<b>Osage University Partners</b>	14
<b>Osage University Partners' Investments</b>	14
<b>Points of Contact at Osage University Partners</b>	14
<b>Strategy Data: Osage University Partners' investments in 2019 and 2020:</b>	14
<b>Research Strategy</b>	14

## PART 5

<b>Top Investors - Biotech: RA Capital, Johnson &amp; Johnson Innovation</b>	15
<b>RA Capital</b>	15

<b>Johnson &amp; Johnson</b>	16
<b>PART 6</b>	
<b>Top Investors - Biotech: IdieBio, US Department of Health</b>	17
<b>IndieBio</b>	17
<b>US Department of Health (HHS)</b>	17
<b>Research Strategy</b>	18
<b>SOURCES</b>	
<b>Part 1 Sources</b>	19
<b>Part 2 Sources</b>	20
<b>Part 3 Sources</b>	23
<b>Part 4 Sources</b>	25
<b>Part 5 Sources</b>	27
<b>Part 6 Sources</b>	29

# Top Investors - Biotech: Alexandria Venture, Perceptive Advisors

---

Alexandria Investment was founded in [1996](#) and is headquartered in [San Francisco](#). Partners Perceptive Advisors was founded in [1999](#) and is headquartered in [New York](#).

## Alexandria Venture Investments

- Alexandria Venture Investments (AVI) is the [venture capital arm](#) of Alexandria Real Estate Equities, which is listed on the New York Stock Exchange with the ticker symbol [ARE](#).
- AVI was founded in [1996](#) to provide "[long-term](#) strategic investment capital " to companies developing "breakthrough [technologies and therapies](#)" in specific sectors.
- The [sectors](#) it invests in are AgTech, technology, diagnostics, biopharma, and research tools.
- It invests at different [stages](#) including, seed, early, and growth-stage.
- In 2018, AVI was named the "[Most Active Biopharma](#) Investor" by new deal volume, by Silicon Valley Bank.
- In the same year, it was named the "[#1 venture capital investor](#) in the healthcare sector by U.S.-based deal volume", by Forbes.
- The company is headquartered in [San Francisco – California](#) and employs 251+ people.

## Investments

- In [April 2020](#), AVI alongside other firms raised [\\$38 million](#) in a Series A funding for the [biotech](#) company Nitrome Biosciences. [Nitrome Biosciences](#) is developing drugs against Nitrases, which is a new class of enzymes. According to the CEO of Nitrome Biosciences, [Dr Irene Griswold-Prenner](#), the investment would enable the company to [forge ahead](#) with its mission of improving the lives of people with neurodegenerative and other age-related diseases.
- In [March 2020](#), AVI also contributed to a [\\$60 million](#) Series A funding for the company Affinia Therapeutics. [Affinia Therapeutics](#) is a biotech company focused on creating "[transformative gene therapies](#)" for devastating genetic diseases.

## Points of Contact

- [Michael Norsen](#) – Principal at Alexandria Venture Investments
- [Catherine Pagliarulo](#) – Principal at Alexandria Venture Investments
- [Hallie Kuhn](#) – Principal at Alexandria Venture Investments

## Data from Initial Research

- [Alexandria Venture Investments](#) (California): [19 deals](#). [Felice Shieh](#) serves has been a principal with the firm since April 2019.

## Perceptive Advisors

- Perceptive Advisors is focused on "[supporting progress](#) in the life sciences industry", by spotting opportunities and administering financial resources towards "[the most promising](#)" technologies in modern healthcare.
- The firm was established in [1999](#) and is headquartered in [New York, New York](#).
- It states that its investments are targeted towards healthcare companies from [small to large](#), who have been identified in their fields as being transformative.
- It also looks out for companies who offer new [therapeutics, devices, or diagnostics](#) with conviction in the healthcare industry.
- The company is made up of [26 team](#) members and has approximately [\\$4.2 billion](#) in assets under management.

## Investments

- In [April 2020](#), Perceptive Advisors was the lead investor in a [\\$55 million](#) Series C investment into the company Dynacure. Dynacure is a [biotech](#) company specialized in the development of clinical-stage drugs for patients with orphan and rare diseases.
- In [March 2020](#), Perceptive Advisors through its Perceptive Xontogeny Venture Fund, invested [\\$21 million](#) in a Series A financing into Zucara Therapeutics. [Zucara Therapeutics](#) is a biotech company focused on creating the "[first, once-daily](#)" therapeutic, for preventing low blood sugar in diabetic patients.

## Points of Contact

- [Joseph Edelman](#) – CEO and [Portfolio Manager](#)
- [Adam Stone](#) – Chief Investment Officer

- [Michael Altman](#) – Managing Director

## Data From Initial Research

- [Perceptive Advisors](#) (New York): [18 deals](#). [Sam Chawla](#) is the portfolio manager and a member of the investment committee.

# Top Investors - Biotech: ARCH Venture Partners, Google Ventures

---

Arch Venture Partners was founded in 1986 and is headquartered in Chicago. Google Ventures was founded in 2009 and is headquartered in Mount View, California.

## Arch Venture Partners

### Overview

- Established in [1986](#), Arch Venture Partners is one of the largest early-stage technology venture firms in the US. The [Chicago-based](#) company has [three](#) offices in the US and one in [Ireland](#).
- Arch Venture Partners has funded more than [250](#) companies with investments ranging from [\\$50,000](#) to over [\\$150 million](#) per company.
- Arch Venture Partners primarily invests in [early-stage](#) life sciences and [physical sciences](#) companies that work in the field of [genomics](#), industrial biotechnology, [nanotechnology](#), and the prevention, detection, and treatment of [major diseases](#).
- The company partners with [national laboratories](#), research universities, corporate research groups, [academic institutions](#), and entrepreneurs.
- The firm has raised capital of more than [\\$4.5](#) billion across its [ten](#) primary funds.

### Investments

- Arch Venture Partners has invested in [10](#) biotech and life sciences companies from January to May 2020. The most recent investments included [Erasca](#), [Rome Therapeutics](#), and [Aspen Neuroscience](#) in April 2020.
- [Erasca](#) raised [\\$200](#) million in [Series B](#) funding led by Arch Venture Partners and Cormorant Asset Management. The company is developing [targeted therapies](#) for cancer treatment.
- [Aspen Neuroscience](#) raised [\\$70](#) million in [Series A](#) funding led by OrbiMed. The company is developing restorative [autologous neuron therapy](#) for the treatment of [Parkinson's disease](#).
- In [April](#) 2020, the company managed to raise [\\$1.46](#) billion for its [two](#) funds to invest in early-stage [biotechnology](#) companies.



- Some portfolio companies that are working to fight the [COVID-19](#) pandemic include Vir Biotechnology, [VBI Vaccines](#), Bii Biosciences, [Alnylam Pharmaceuticals](#), Sana Biotechnology, [Quanterix](#), Twist Biosciences, and Bellerophon. It is noted that none of the investments were made in these companies over the past [five months](#).

## Points of Contact

- [Carol Suh](#) – Principal
- [Kristina Burow](#) – Managing Director
- [Thomas Daniel](#) – Venture Partner
- [Jonathan Lim, M. D](#) – Venture Partner

## Initial Research

- [Arch Venture Partners](#) (Illinois): [16 deals](#). The principal is [Ari Nowacek](#).

## Google Ventures (GV)

### Overview

- Google Ventures was spun out of Google in [2009](#), and it is the venture capital subsidiary of [Alphabet, Inc.](#) The company is headquartered in [Mountain View](#), California, and has offices located in Boston, San Francisco, [New York](#), and London.
- The [venture capital](#) funding company invests in bold new companies across the domains of [life science](#), consumer products and services, [enterprise technology](#), and frontier technology.
- GV manages an active portfolio of [300](#) companies, valued at [\\$4.5](#) billion. The company facilitates [startups](#) with unique technology powered by Google.

### Investments

- [GV](#) has invested in [40](#) biotech companies out of [71](#) companies in its life sciences portfolio.
- The company has invested in [9](#) biotech startups over the last five months, i.e., between January to May 2020. The recent investments included [Owkin](#), [Ventus Therapeutics](#), [ROME Therapeutics](#), [Accent Therapeutics](#), [Aledade](#), [Cerevance](#), [Element Science](#), [Verana Health](#), and [EQRx](#).
- [Rome Therapeutics](#) raised [\\$50](#) million in [Series A](#) funding led by Google Ventures. The CEO incubated the company in the [entrepreneur-in-residence](#) at GV. Rome is developing novel therapies for cancer and [autoimmune diseases](#) with the use of repeatome or [repetitive](#)

[sequences](#) of nucleic acids.

- [Accent Therapeutics](#) raised \$63 million in [Series B](#) funding led by [EcoR1 Capital](#) and involved participation by [Google Ventures](#), Droia Ventures, AbbVie Ventures, and others. The company is developing breakthrough treatments for [cancer patients](#) by targeting RNA-modifying proteins ([RMPs](#)).

## Points of Contact

- [Bethany Tsui](#) – Principal
- [Blake Byers](#) – General Partner
- [Anthony Philippakis](#) – Venture Partner
- [Ben Robbins](#) – Venture Partner

## Initial Research

- [Google Ventures](#) (California): [15 deals](#). The principal is [Terri C. Burns](#).

# Top Investors - Biotech: Boxer Capital, OrbiMed

---

Boxer Capital is based in San Diego, California, and invests in drug development. OrbiMed is a private investment firm based in New York and was established in 1989.

## Boxer Capital

- Boxer Capital is based in San Diego, California. The firm invests in "[drug development](#) across multiple therapeutic indications".
- Boxer Capital was established in [2005](#) by Tavistock Group.
- The firm invests in companies that have goals of improving medicine. Boxer Capital's research and investment team identifies investment opportunities "throughout the [business life-cycle](#)".

## Investments

- Boxer Capital has invested in a total of [seven](#) biotechnology companies in the past five months. Examples include [Pandion Therapeutics](#) and Tango Therapeutics.
- In early April 2020, Boxer Capital led a [\\$60 million](#) Series B financing round for Tango Therapeutics. Tango Therapeutics is "a biotech company focused on discovering and delivering the next generation of targeted [cancer therapies](#)".
- Boxer Capital also participated in an [\\$80 million](#) Series B financing round for Pandion Therapeutics, Inc in early April 2020. Pandion Therapeutics is a biotech company with the aim of finding the treatment of autoimmune disorders.

## Additional Points of Contact

- Ivan Lieberburg is a [managing director](#) at Boxer Capital. [Here](#) is the link to his LinkedIn account.
- Kristen Cohen is the [director of administration](#) at Boxer Capital. [Here](#) is the link to her LinkedIn account.
- Mark Janssens is the [director of trading](#) at Boxer Capital. [Here](#) is the link to his LinkedIn account.

## OrbiMed

- OrbiMed is a private investment firm based in [New York](#). The company invests in [biopharmaceuticals](#), medical devices, healthcare services, and diagnostics innovations globally.
- The investment business was established in [1989](#).

## Investments

- OrbiMed has invested in a total of [ten](#) biotechnology companies in the past five months. Examples include Pandion Therapeutics and Aspen Neuroscience.
- In March 2020, OrbiMed participated in an [\\$80 million](#) Series A financing round for ReCode. ReCode is a private biotech company "pioneering [precision medicines](#) for pulmonary diseases".
- April 01, 2020, OrbiMed led a [\\$70 million](#) Series A financing round for Aspen Neuroscience. Aspen Neuroscience is a "private biotechnology company developing the [first autologous neuron](#) replacement therapy to treat Parkinson's disease".

## Additional Points of Contact

- Stephen Squinto is an executive partner at OrbiMed. [Here](#) is the link to his LinkedIn account.
- Carl L. Gordon is a founding "partner and [co-head](#) of Global Private Equity" at OrbiMed. [Here](#) is the link to his LinkedIn account.
- Carter Neild is a [general partner](#) at OrbiMed. [Here](#) is the link to his LinkedIn account.

# Top Investors - Biotech: Redmile Group, Osage University Partners

---

Redmile Group invests in healthcare companies, while Osage University Partners (OUP) strictly invests in startups that are developing pioneering technologies. Redmile has assets worth \$4.18 billion, while OUP has about \$600 million under management.

## Redmile Group

- Founded in [2007](#), Redmile is a US-based "[healthcare](#) and life sciences investment firm" that has assets worth [\\$4.18 billion](#).
- It has [locations](#) in San Francisco, California and New York City, New York.
- Redmile focuses on "[venture](#), growth and crossover investing across healthcare."

## Biotech Investments

- In February 2020, Redmile collaborated with Sofinnova Partners to invest [£26.3 million](#) in Redx Pharma, which is a "UK-based oncology and fibrotic disease focused [biotech company](#)." Additionally, Redmile is providing "[£5 million](#) of short-term debt funding" to Redx. After the investment, Jeremy Green, the founder and portfolio manager of Redmile, said, "[Redx](#), with its deep expertise in medicinal chemistry, has a proven track record of designing high quality, commercially attractive molecules that have the potential to be effective drugs to treat significant unmet medical conditions."
- Redmile's most recent biotech investment was in LifeSprout, a "[regenerative medicine company](#) founded with technology licensed from Johns Hopkins University." Redmile's investment helped LifeSprout close "a [\\$28.5 million](#) Series A financing," which the firm will use toward developing products from its [Regenerative Matrix](#) platform. The Regenerative Matrix platform consists of "[biomimetic](#), biocompatible materials engineered to look and feel like natural tissue."

## Points of Contact at Biotech

- [Natalie Berner](#) is Redmile's vice president.
- [Joshua Garcia](#) is Redmile's CFO.
- [Amrit Nagpal](#) is Redmile's managing director.

## Strategy Data: Biotech's investments in 2019 and 2020:

- [Redmile Group](#) (California): [14 deals](#) . [Jeremy Green](#) is the portfolio manager at Redmile.

## Osage University Partners

- Based in [Bala Cynwyd, Pennsylvania](#), Osage University Partners (OUP) is a venture capital fund that invests in startups that are "[developing pioneering technologies](#) in partnership with the top" national and international research institutions.
- OUP has partnered with more than 100 universities to support over [90 startups](#).
- OUP has about "[\\$600 million](#) under management."

## Osage University Partners' Investments

- In March 2020, OUP invested in ReCode Therapeutics, "a [biotech startup](#) focused on precision medicine for pulmonary diseases." OUP's investment helped ReCode close "an [\\$80 million Series A round](#)."
- In October 2019, OUP made an [investment](#) in IonQ, a Maryland-based quantum computing company. The investment helped the firm raise \$55 million in funding, which IonQ wants to put toward commercializing its own [quantum computing platform](#).

## Points of Contact at Osage University Partners

- [Louis Berneman](#) is OUP's founding partner.
- [William Harrington](#) is OUP's managing partner.
- [Matthew Cohen](#) is OUP's partner and [principal of life science](#).
- [Kirsten Leute](#) is OUP's partner of university relations.

## Strategy Data: Osage University Partners' investments in 2019 and 2020:

- [Osage University Partners](#) (Pennsylvania): [12 deals](#) . [Stephanie Stehman](#) is the [principal of life science](#).

## Research Strategy

After searching Osage University Partners' website and social media platforms, as well as news publications, we found that OUP made only one biotech investment in the past five months. However, we expanded our research and discovered that OUP's last biotech investment in 2019 was in IonQ. Therefore, we've included this information above.

# Top Investors - Biotech: RA Capital, Johnson & Johnson Innovation

---

In the past five months RA Capital Management has invested in the biotechnology companies Pandion Therapeutics and the Legend Biotech Corporation, while Johnson & Johnson Innovation has also invested in the Legend Biotech Corporation. Additionally, Johnson & Johnson Innovation has invested in Adicet Bio.

## RA Capital

- Located in [Boston, Massachusetts](#), RA Capital Management operates as a multi-stage investment manager that employs between 51 and 200 individuals, according to its LinkedIn profile. The types of companies that RA Capital Management typically invests in include [life science and healthcare](#) entities that actively create diagnostics, drugs, and medical devices. Founded in the year [2004](#), its [investment team principals](#) are Matthew Hammond, Jake Simson, Parker Cassidy, Derek DiRocco and Zach Scheiner.
- Additional points of contact at RA Capital Management include the team's managing director [Josh Resnick](#) and venture associates [Nathanial Brooks Horwitz](#) and [Chieze Ibeneche-Nnewihe](#).
- It has invested in [22](#) different biotech companies, including [12](#) during 2019 and 2020. In the past five months, RA Capital has invested in a total of [nine](#) biotechnology companies, such as Pandion Therapeutics and Legend Biotech.
- In early April 2020, RA Capital Management participated in an \$80 million Series B financing round for [Pandion Therapeutics, Inc.](#), which acts as a clinical-stage biotechnology businesses that develops modular protein therapeutics meant for inflammatory and autoimmune illnesses. The company is currently headquartered in [Cambridge, Massachusetts](#). Its chief executive officer is [Rahul Kakkar](#), and [Jo Viney](#) serves as its co-founder, president, and chief scientific officer.
- Also in early April 2020, RA Capital Management partook in a \$150.5 million Series A financing round for the [Legend Biotech Corporation](#). Legend Biotech is a clinical-stage biopharmaceutical business that focuses on the uncovering and progression of [innovative cell therapies](#) for indications such as oncology. The company plans to use the funds raised from this financing round to accelerate the development, commercialization, and research of its pipeline programs, as well as to expand its manufacturing establishments and improve "its [research and development platform](#)."

- Founded in 2014 and headquartered in [Piscataway, New Jersey](#), Yuan Xu is Legend Biotech's chief executive officer, and [Frank Fan](#) serves as its chief scientific officer and co-founder.

## Johnson & Johnson

- Johnson & Johnson Innovation consists of a network of [complementary groups](#) that offer significant tactics and solutions to promote collaborations. JJDC acts as Johnson & Johnson's [strategic venture capital division](#). The group focuses its investments on providers of [consumer healthcare](#), pharmaceuticals, and medical devices. Situated in [Cambridge, Massachusetts](#), its venture investments principal is [Vijay Murthy](#).
- Additional points of contact include [Tamir Meiri](#) (senior manager of Venture Investments), [Nicholas Mourlas](#) (senior director of New Ventures), and [Kara Bortone](#) (senior director of sourcing and portfolio management).
- The group has invested in a total of [25](#) biotech companies, including [11](#) during 2019 and 2020.
- In the past five months, Johnson & Johnson Innovation has only made one investment in a biotechnology company, [Legend Biotech](#). In early April, Johnson & Johnson Innovation participated in a \$150.5 million Series A financing round for the [Legend Biotech Corporation](#).
- However, it has invested in about [six](#) biotechnology companies in the past 12 months (including Legend Biotech), such as Adicet Bio. In early October 2019, Johnson & Johnson Innovation took part in an \$80 million Series B financing round for [Adicet Bio, Inc.](#) Adicet Bio is a pre-clinical stage biotechnology business that develops [allogeneic cell therapies](#) designed for cancer by utilizing gamma delta T cells.
- Situated in [Menlo Park, California](#), [Anil Singhal](#) is Adicet Bio's chief executive officer and president, and [Stewart Abbot](#) is its chief operating officer and chief scientific officer.
- Additionally, it participated in a \$100 million equity financing round for [RefleXion Medical](#), a company in which it had already had previous investments in, in mid-April 2020. Headquartered in Hayward, California, RefleXion Medical operates as a therapeutic oncology organization that utilizes [biology-guided radiotherapy](#) to help cancer patients. The company's chief executive officer is [Todd Powell](#).



# Top Investors - Biotech: IdieBio, US Department of Health

---

IndieBio invests \$250,000 in fifteen early stage biology companies every six months. The HHS is the official government body that awards funding to select biology companies. Their funding for 2020 amounted to over \$87 billion.

## IndieBio

- IndieBio is investing \$250,000 in startups that are focused on developing “[diagnostics](#), [therapeutics](#), vaccines, disinfection, and other solutions addressing the worldwide problem of emerging infectious diseases.”
- Every six months, [fifteen early stage biology](#) companies are selected for training in downtown San Francisco.
- They have invested over [\\$2.4 billion in 116](#) biology companies to date.
- The company also opened a new office in [Manhattan, New York](#) recently.
- While we were not able to find any specific investments that IndieBio has made in the last month in biotech companies specifically, we did find that SOSV, their parent company, invested in Nordetect, a Copenhagen-based biotech company that produces “[biosensors](#), [hardware and data management](#) systems for precision agriculture.”
- We did, however, find that IndieBio is in the process of selecting [8 biotech companies](#) that are working on coronavirus-tech.
- Contact information: [Sam Lee](#) (Program Director), [Julie Wolf](#) (Communications Director), [Arvind Gupta](#) (Managing Director), and [Alex Kopeylan](#) (Program Director and Partner).

## US Department of Health (HHS)

- The US Department of Health provides grants to multiple biology companies to “[enhance and protect the health](#) and well-being of all Americans.”
- Their budget for 2020 is “[\\$87.1 billion in discretionary budget](#) authority and \$1.2 trillion in mandatory funding.”
- On March 31, Cure Health was awarded [\\$13 million in funding](#) by the HHS to develop a portable molecular test for the detection of the presence of the SARS-CoV-2 virus.

- On March 30, 2020, the HHS announced a [collaboration with Johnson & Johnson](#) for the development of clinical tests and COVID-19 vaccines. Johnson & Johnson will invest \$1 billion with the joint collaboration of the HHS to develop over 1 billion vaccines for the virus.
- The HHS also announced that it will support [Moderna](#) to speed up the Phase 2 and 3 clinical trials of its COVID-19 vaccine, SARS-CoV-2 mRNA-1273.
- Alex M Azar is the [Secretary of the HHS](#). His phone number is 202-690-7000 and his email is secretary@HHS.gov . He does not have a LinkedIn account but his Twitter account can be found [here](#).
- Other Contact information: [Donald Rucker](#) (National Coordinator for Health Information Technology), [Michael Caputo](#) (Assistant Secretary of HHS).

## Research Strategy

While information for the HHS was readily available, information on the investments made by IndieBio in the last 5 months was not. We looked through the company's portfolio, press releases and industry publication like the IEEE, PR Newswire, and TechCrunch but we could not find any evidence that IndieBio has invested in any biotech companies since the beginning of January. The did invest in two agritech start-ups but the majority of the investments were made by their parent company, SOSV. It is also possible that they were saving their capital for the [8 biotech companies](#), which they are in the process of selecting.

## Part 1 Sources

---

### 1) Venture Investments

<https://www.ave.com/venture-investments.html>

### 2) Alexandria Real Estate Equities (ARE) Stock Price, Quote, History & News - Yahoo Finance

<https://finance.yahoo.com/quote/ARE/>

### 3) Alexandria Venture Investments - Crunchbase

<https://www.crunchbase.com/organization/alexandria-venture#section-overview>

### 4) Nitrome Biosciences - Crunchbase

<https://www.crunchbase.com/organization/nitrome-biosciences>

### 5) Nitrome Biosciences Raises \$38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases

<https://www.businesswire.com/news/home/20200421005787/en/Nitrome-Biosciences-Raises-38M-Series-Financing-Advance>

### 6) Affinia Therapeutics Raises \$60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies

<http://www.globenewswire.com/news-release/2020/03/31/2009133/0/en/Affinia-Therapeutics-Raises-60M-in-Series-A-Financing-to-Advance-Rational-Design-AAV-Platform-and-Transformative-Gene-Therapies.html>

### 7) Affinia Therapeutics - Crunchbase

<https://www.crunchbase.com/organization/affinia-therapeutics>

### 8) Michael Norsen - LinkedIn

<https://www.linkedin.com/in/michael-norsen-bb7a053/>

### 9) Catherine - LinkedIn

<https://www.linkedin.com/in/catherinepagliarulo/>

### 10) Hallie Kuhn - LinkedIn

<https://www.linkedin.com/in/hallie-kuhn-63164379/>

### 11) See the Most Active Investors Behind the \$14.92 Billion Invested into Life Science Companies since 2019 - Cipher Bio

<https://cipherbio.com/blog/see-the-top-life-science-investors-in-2019-2020/>

### 12) Felice Shieh

<https://www.linkedin.com/in/felice-shieh-phd-mba-2976801/>

### 13) Perceptive Advisors

<https://www.perceptivelife.com>

### 14) ABOUT US | Perceptive Advisors

<https://www.perceptivelife.com/about-us/>

### 15) INVESTMENTS | Perceptive Advisors

<https://www.perceptivelife.com/investments/>

### 16) Dynacure Announces €50M (\$55M) Series C Financing

<https://www.prnewswire.com/news-releases/dynacure-announces-50m-55m-series-c-financing-301033572.html>

### 17) Dynacure - Crunchbase

<https://www.crunchbase.com/organization/dynacure#section-overview>

### 18) Zucara Therapeutics Announces US\$21 Million Series A Financing

<http://www.globenewswire.com/news-release/2020/03/31/2009109/0/en/Zucara-Therapeutics-Announces-US-21-Million-Series-A-Financing.html>

### 19) Zucara Therapeutics - Crunchbase

<https://www.crunchbase.com/organization/zucara-therapeutics#section-overview>

### 20) Joseph Edelman

<https://www.linkedin.com/in/joe-edelman-65b4857/>

### 21) TEAM | Perceptive Advisors

<https://www.perceptivelife.com/team/>

### 22) Adam Stone

<https://www.linkedin.com/in/adam-stone-0b0a551/>

### 23) Michael Altman

<https://www.linkedin.com/in/michael-altman-36a1672/>

## Part 2 Sources

---

### 1) ARCH Venture Partners

<https://www.crunchbase.com/organization/arch-venture-partners#section-overview>

## 2) ARCH Venture Partners

<https://www.linkedin.com/company/arch-venture-partners/about/>

## 3) Contact - Arch Venture Partners

<https://www.archventure.com/contact/>

## 4) Vizgen Launches with \$14M Series A Financing Led by ARCH Venture Partners and Northpond Ventures

<https://www.prnewswire.com/news-releases/vizgen-launches-with-14m-series-a-financing-led-by-arch-venture-partners-and-northpond-ventures-300996237.html>

## 5) About - Arch Venture Partners

<https://www.archventure.com/about/>

## 6) ARCH Venture Partners Announces \$1.46 Billion Raised in Two New Funds to Invest in Transformative Biotechnology Companies

<https://www.prnewswire.com/news-releases/arch-venture-partners-announces-1-46-billion-raised-in-two-new-funds-to-invest-in-transformative-biotechnology-companies-301033707.html>

## 7) Rome Therapeutics launches to probe junk DNA for cancer drug discovery

<https://cen.acs.org/pharmaceuticals/oncology/Rome-Therapeutics-launches-probe-junk/98/web/2020/04>

## 8) Erasca Raises \$200 Million Series B Financing

<https://www.businesswire.com/news/home/20200427005115/en/Erasca-Raises-200-Million-Series-Financing>

## 9) Aspen Neuroscience Announces \$70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy to Treat Parkinson Disease

<https://www.prnewswire.com/news-releases/aspen-neuroscience-announces-70-million-series-a-financing-led-by-orbimed-to-advance-development-of-the-first-autologous-neuron-replacement-therapy-to-treat-parkinson-disease-301033098.html>

## 10) GV

<https://www.crunchbase.com/organization/google-ventures#section-overview>

## 11) GV

<https://www.linkedin.com/company/gv/about/>

## 12) GV / Press

<http://gv.com/press>

## 13) GV

<http://gv.com>

14) See the Most Active Investors Behind the \$14.92 Billion Invested into Life Science Companies since 2019 - Cipher Bio

<https://cipherbio.com/blog/see-the-top-life-science-investors-in-2019-2020/>

15) Accent Therapeutics Announces \$63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting RNA-Modifying Proteins - Accent Therapeutics

<https://www.accenttx.com/press-releases/accent-therapeutics-announces-63-million-series-b-financing-to-advance-novel-precision-cancer-therapies-targeting-rna-modifying-proteins/>

16) Rome Therapeutics Raises \$50M in Series A Financing | FinSMEs

<https://www.finsmes.com/2020/04/rome-therapeutics-raises-50m-in-series-a-financing.html>

17) Ventus Therapeutics Launches with \$60 Million Series A

<https://www.businesswire.com/news/home/20200506005211/en/Ventus-Therapeutics-Launches-60-Million-Series>

18) Owkin raises \$25 million as it builds a secure network for healthcare analysis and research – TechCrunch

<https://social.techcrunch.com/2020/05/07/owkin-raises-25-million-as-it-builds-a-secure-network-for-healthcare-analysis-and-research/>

19) Aledade Raises \$64 Million Series C on Nationwide Growth of Value-Based Care Network

<https://www.aledade.com/aledade-raises-64-million-series-c-nationwide-growth-value-based-care-network>

20) Build Query: Funding Rounds

[https://www.crunchbase.com/search/funding\\_rounds/field/principal.investors/num\\_investments\\_funding\\_rounds/google-ventures?timeline=true&timelineType=all](https://www.crunchbase.com/search/funding_rounds/field/principal.investors/num_investments_funding_rounds/google-ventures?timeline=true&timelineType=all)

21) Cerevance Closes \$45 Million Series B Financing

<http://www.globenewswire.com/news-release/2020/04/14/2015787/0/en/Cerevance-Closes-45-Million-Series-B-Financing.html>

22) Element Science collects nearly \$150M Series C for wearable personal defibrillator patch

<https://www.mobihealthnews.com/news/element-science-collects-nearly-150m-series-c-wearable-personal-defibrillator-patch>

23) Why We're Investing in EQRx - Andreessen Horowitz

<https://a16z.com/2020/01/12/why-were-investing-in-eqrx/>

24) Alphabet's GV leads \$100M investment in Verana Health - MedCity News

<https://medcitynews.com/2020/02/alphabets-gv-leads-100m-investment-in-verana-health/>

25) See the Most Active Investors Behind the \$14.92 Billion Invested into Life Science

## Companies since 2019 - Cipher Bio

<https://cipherbio.com/blog/see-the-top-life-science-investors-in-2019-2020/>

### 26) Ari Nowacek, M.D, Ph.D. - Arch Venture Partners

<https://www.archventure.com/team/ari-nowacek/>

### 27) Untitled

<https://www.linkedin.com/in/tcburning/>

### 28) Untitled

<https://www.linkedin.com/in/tsuibethany/>

### 29) Untitled

<https://www.linkedin.com/in/carolsuh/>

### 30) Untitled

<https://www.linkedin.com/in/blbyers/>

### 31) Untitled

<https://www.linkedin.com/in/anthony-philippakis-83a2656/>

### 32) Untitled

<https://www.linkedin.com/in/kristina-burow-4a8836b/>

### 33) Untitled

<https://www.linkedin.com/in/thomas-daniel-8162aa12/>

### 34) Untitled

<https://www.linkedin.com/in/jonathan-lim-m-d-317b3/>

### 35) Untitled

<https://www.linkedin.com/in/ben-robbins-338794a/>

## Part 3 Sources

---

### 1) Biotech Investment Fund | Boxer Capital | Tavistock Group

<https://www.boxercap.com>

### 2) Private Investment Firm | Boxer Capital | Tavistock Group

<https://www.boxercap.com/about-us/>

3) Untitled

<https://www.linkedin.com/company/orbimed-advisors/about/>

4) OrbiMed

<http://www.orbimed.com/en/about-us>

5) Untitled

<https://www.americaninno.com/boston/roundups-boston/april-funding-update-54-boston-startups-raise-roughly-3-5-billion-in-venture-funding/>

6) Aspen Neuroscience Announces \$70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy to Treat Parkinson Disease

<https://www.prnewswire.com/news-releases/aspen-neuroscience-announces-70-million-series-a-financing-led-by-orbimed-to-advance-development-of-the-first-autologous-neuron-replacement-therapy-to-treat-parkinson-disease-301033098.html>

7) Untitled

<https://www.crunchbase.com/organization/boxer-capital#section-investments>

8) Untitled

<https://www.crunchbase.com/organization/orbimed-advisors#section-lists-featuring-this-company>

9) Untitled

<https://www.linkedin.com/in/stephen-squinto-bb99499/>

10) Leadership

<http://www.orbimed.com/en/leadership/partners?mid=1170>

11) Untitled

<https://www.linkedin.com/in/carl-gordon-b4583247/>

12) Leadership

<http://www.orbimed.com/en/leadership/partners?mid=1172>

13) Untitled

<https://www.linkedin.com/in/carter-neild-1b521911/>

14) Untitled

<https://www.linkedin.com/in/imlieb/>

15) Our Biotech Investment Team | Boxer Capital | Tavistock Group



<https://www.boxercap.com/our-team/>

16) Untitled

<https://www.linkedin.com/in/kristen-cohen-59897387/>

17) Our Biotech Investment Team | Boxer Capital | Tavistock Group

<https://www.boxercap.com/our-team/>

18) Untitled

<https://www.linkedin.com/in/mark-janssens-6aa92b5/>

19) ReCode Therapeutics Raises \$80 Million in Oversubscribed Series A Financing | BioSpace

<https://www.biospace.com/article/-recode-therapeutics-raises-80-million-in-oversubscribed-series-a-financing/>

## Part 4 Sources

---

1) Redx agrees funding from Redmile Group, LLC & Sofinnova Partners | Redx Pharma Plc

<https://www.redxpharma.com/news-archive/redx-agrees-funding-from-redmile-group-llc-sofinnova-partners/>

2) Redx Pharma jumps on funding package from Redmile and Sofinnova Partners - Vox Markets

<https://www.voxmarkets.co.uk/articles/redx-pharma-jumps-on-funding-package-from-redmile-and-sofinnova-partners-bfa27ef/>

3) Redmile Group

<http://redmilegroup.com/>

4) Redmile Group

<https://www.crunchbase.com/organization/redmile-group#section-overview>

5) Natalie Berner

<https://www.linkedin.com/in/natalie-berner-4b952b83/>

6) See the Most Active Investors Behind the \$14.92 Billion Invested into Life Science Companies since 2019 - Cipher Bio

<https://cipherbio.com/blog/see-the-top-life-science-investors-in-2019-2020/>

7) Jeremy Green

<https://www.linkedin.com/in/jeremy-green-3b82301/>

8) Joshua Garcia

<https://www.linkedin.com/in/joshua-garcia-67b1b28/>

9) Amrit Nagpal

<https://www.linkedin.com/in/amrit-nagpal-b15652a0/>

10) LifeSprout Secures \$28.5M Series A Funding

<https://vcnewsdaily.com/lifesprout/venture-capital-funding/bsjdqqlzt>

11) Osage University Partners - Venture Capital Fund for University Startups

<https://oup.vc>

12) Stephanie Stehman

<https://www.linkedin.com/in/stephanie-stehman-ph-d-9925754/>

13) Stephanie Stehman - Osage University Partners

<https://oup.vc/team/stephanie-stehman/>

14) Louis Berneman

<https://www.linkedin.com/in/louis-berneman-9b861a7/>

15) William Harrington

<https://www.linkedin.com/in/billharringtonoup/>

16) Matthew Cohen

<https://www.linkedin.com/in/matthew-cohen-b3679424/>

17) Matt Cohen - Osage University Partners

<https://oup.vc/team/matthew-cohen/>

18) Kirsten Leute

<https://www.linkedin.com/in/kirstenleute/>

19) Osage University Partners

<https://www.linkedin.com/company/osage-university-partners/about/>

20) Following Merger, ReCode Therapeutics Lands \$80M Series A

<https://www.americaninno.com/northtexas/news-northtexas/following-merger-recode-therapeutics-lands-80m-series-a/>

21) TQD Exclusive: 20 Companies Investing in Quantum Computing

<https://thequantumdaily.com/2020/04/13/tqd-exclusive-20-companies-investing-in-quantum-computing/>

22) IonQ Raises \$55M in Funding | FinSMEs

## Part 5 Sources

---

1) RA Capital | About Us

<https://racap.com/about-us>

2) CipherBio - RA Capital Management

[https://www.cipherbio.com/data-viz/investor/%7B%7BngMeta.og\\_url%7D%7D](https://www.cipherbio.com/data-viz/investor/%7B%7BngMeta.og_url%7D%7D)

3) LinkedIn - RA Capital Management

<https://www.linkedin.com/company/ra-capital-management-llc>

• “ ”

4) See the Most Active Investors Behind the \$14.92 Billion Invested into Life Science Companies since 2019 - Cipher Bio

<https://cipherbio.com/blog/see-the-top-life-science-investors-in-2019-2020/>

5) RA Capital | Team Page

<https://racap.com/about-us/our-team>

6) Pandion Therapeutics Announces Close of \$80 Million Series B Financing

<https://www.businesswire.com/news/home/20200401005112/en/Pandion-Therapeutics-Announces-Close-80-Million-Series>

7) Legend Biotech Raises \$150.5 Million in Series A Preferred Financing To Advance its Oncology Pipeline and Platform

[https://www.legendbiotech.com/pdf/LEGN\\_IR\\_04012020v2.pdf](https://www.legendbiotech.com/pdf/LEGN_IR_04012020v2.pdf)

8) Leadership - Pandion Therapeutics

<https://pandiontx.com/about/leadership/>

9) LinkedIn- Legend Biotech

<https://www.linkedin.com/company/legendbiotechco./>

10) Legend Biotech

<https://www.legendbiotech.com/index.html>

11) LinkedIn - Joshua Resnick

<https://www.linkedin.com/in/joshuaresnick>

12) LinkedIn - Nathaniel Brooks Horwitz

<https://www.linkedin.com/in/nathaniel-brooks-horwitz>

13) LinkedIn - Chieze Ibeneche-Nnewihe

<https://www.linkedin.com/in/chiezeibenechennewihe>

14) Crunchbase - RA Capital

<https://www.crunchbase.com/organization/ra-capital-management#section-investments>

15) About us | JNJ Innovation

<https://jnjinnovation.com/about-us>

16) Johnson & Johnson Innovation – JJDC, Inc. | JNJ Innovation

<https://jnjinnovation.com/jjdc>

17) LinkedIn - Vijay Murthy

<https://www.linkedin.com/in/vijaymurthy/>

18) LinkedIn - Tamir Meiri

<https://il.linkedin.com/in/tamir-meiri-694a9b10>

19) CipherBio - Johnson & Johnson Innovation

[https://www.cipherbio.com/data-viz/investor/%7B%7BngMeta.og\\_url%7D%7D](https://www.cipherbio.com/data-viz/investor/%7B%7BngMeta.og_url%7D%7D)

20) LinkedIn - Nicholas Mourlas

<https://www.linkedin.com/in/nicholas-mourlas-36623>

21) LinkedIn - Kara Bortone

<https://www.linkedin.com/in/kara-bortone-a7846b27>

22) Crunchbase - Johnson & Johnson Innovation

<https://www.crunchbase.com/organization/johnson-johnson-innovation#section-investments>

23) Legend Biotech Raises \$150.5M Series A Funding

<https://vcnewsdaily.com/legend-biotech/venture-capital-funding/qnknvszfpq>

24) Adicet Bio Raises \$80M in Series B Financing | Markets Insider

<https://markets.businessinsider.com/news/stocks/adicet-bio-raises-80m-in-series-b-financing-1028572383>

25) Leadership and Board of Directors for Adicet Bio

<https://www.adicetbio.com/about/>

26) Contact Adicet Bio | 200 Constitution Drive | Menlo Park CA 94025

<https://www.adicetbio.com/contact/>

27) Business Wire

<https://www.businesswire.com/servererror.html>

## Part 6 Sources

---

1) About - IndieBio

<https://indiebio.co/about/>

2) Nordetect secured capital investment from Rockstart, PreSeed Ventures, SOSV, and Luminate Venture Corp.

<https://nordic9.com/news/nordetect-secured-capital-investment-from-rockstart-preseed-ventures-sosv-and-luminate-venture-corp-news6385316719/>

3) Untitled

<https://www.linkedin.com/in/sam-lee-089155/>

4) Full Page Reload

<https://spectrum.ieee.org/view-from-the-valley/at-work/start-ups/indiebio-eight-coronavirus-tech-startups-funding>

5) Untitled

<https://www.linkedin.com/in/julie-wolf-552b7566/>

6) Untitled

<https://www.linkedin.com/in/alex-kopelyan-66b16726/>

7) Arvind Gupta

<https://sosv.com/team/arvind-gupta>

8) Alex M. Azar II

<https://www.hhs.gov/about/leadership/secretary/alex-m-azar/index.html>

9) Secretary Alex Azar (@SecAzar) | Twitter

<https://twitter.com/secazar>

10) Untitled

<https://www.linkedin.com/in/donruckermd/>

11) Untitled

<https://www.linkedin.com/in/michael-r-caputo/>

12) Cue Health awarded \$13 million government contract to develop portable, point-of-care COVID-19 test – TechCrunch

<https://social.techcrunch.com/2020/03/31/cue-health-awarded-13-million-government-contract-to-develop-portable-point-of-care-covid-19-test/>

13) HHS FY 2020 Budget in Brief

<https://www.hhs.gov/about/budget/fy2020/index.html>

14) About HHS

<https://www.hhs.gov/about/index.html>

15) US Selects Two COVID-19 Vaccine Candidates for Huge Investments

<https://www.the-scientist.com/news-opinion/us-selects-two-covid-19-vaccine-candidates-for-huge-investments--67367>